Literature DB >> 22091032

3-Allyl-6-bromo-1H-imidazo[4,5-b]pyridin-2(3H)-one.

Siham Dahmani, Youssef Kandri Rodi, Santiago V Luis, Michael Bolte, Lahcen El Ammari.   

Abstract

In the mol-ecule of the title compound, C(9)H(8)BrN(3)O, the fused-ring system is almost planar, the largest deviation from the mean plane being 0.008 (3) Å. The plane through the atoms forming the allyl group is roughly perpendicular to the imidazo[4,5-b]pyridin-2-one system, as indicated by the dihedral angle between them of 70.28 (11)°. In the crystal, each mol-ecule is linked to its symmetry equivalent about the center of inversion by a pair of strong N-H⋯O hydrogen bond, forming inversion dimers.

Entities:  

Year:  2011        PMID: 22091032      PMCID: PMC3213453          DOI: 10.1107/S1600536811025037

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For background to the biological activity of imidazopyridines, see: Chen & Dost (1992 ▶); Cappelli et al. (2006 ▶); Weier et al. (1993 ▶, 1994 ▶); Kulkarni & Newman (2007 ▶). For background to their pharmacological activity, see: Bavetsias et al. (2007 ▶, 2010 ▶).

Experimental

Crystal data

C9H8BrN3O M = 254.09 Triclinic, a = 4.5138 (5) Å b = 9.7750 (9) Å c = 11.5717 (11) Å α = 78.748 (2)° β = 82.526 (3)° γ = 86.038 (2)° V = 496.00 (9) Å3 Z = 2 Mo Kα radiation μ = 4.11 mm−1 T = 571 K 0.60 × 0.19 × 0.04 mm

Data collection

Bruker CCD three-circle diffractometer Absorption correction: multi-scan (SADABS; Sheldrick, 1996 ▶) T min = 0.192, T max = 0.850 3086 measured reflections 2019 independent reflections 1683 reflections with I > 2σ(I) R int = 0.026

Refinement

R[F 2 > 2σ(F 2)] = 0.046 wR(F 2) = 0.127 S = 1.09 2019 reflections 127 parameters H-atom parameters constrained Δρmax = 0.89 e Å−3 Δρmin = −0.82 e Å−3 Data collection: SMART (Bruker, 1997 ▶); cell refinement: SAINT (Bruker, 1997 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: ORTEP-3 for Windows (Farrugia, 1997 ▶); software used to prepare material for publication: WinGX (Farrugia, 1999 ▶). Crystal structure: contains datablock(s) I, global. DOI: 10.1107/S1600536811025037/sj5172sup1.cif Structure factors: contains datablock(s) I. DOI: 10.1107/S1600536811025037/sj5172Isup2.hkl Supplementary material file. DOI: 10.1107/S1600536811025037/sj5172Isup3.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C9H8BrN3OZ = 2
Mr = 254.09F(000) = 252
Triclinic, P1Dx = 1.701 Mg m3
Hall symbol: -P 1Mo Kα radiation, λ = 0.71073 Å
a = 4.5138 (5) ÅCell parameters from 2019 reflections
b = 9.7750 (9) Åθ = 1.8–26.4°
c = 11.5717 (11) ŵ = 4.11 mm1
α = 78.748 (2)°T = 571 K
β = 82.526 (3)°Fiber, colourless
γ = 86.038 (2)°0.60 × 0.19 × 0.04 mm
V = 496.00 (9) Å3
Bruker CCD three-circle diffractometer2019 independent reflections
Radiation source: fine-focus sealed tube1683 reflections with I > 2σ(I)
graphiteRint = 0.026
ω scansθmax = 26.4°, θmin = 1.8°
Absorption correction: multi-scan (SADABS; Sheldrick, 1996)h = −5→5
Tmin = 0.192, Tmax = 0.850k = −12→11
3086 measured reflectionsl = −12→14
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.046Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.127H-atom parameters constrained
S = 1.09w = 1/[σ2(Fo2) + (0.0649P)2 + 0.1269P] where P = (Fo2 + 2Fc2)/3
2019 reflections(Δ/σ)max < 0.001
127 parametersΔρmax = 0.89 e Å3
0 restraintsΔρmin = −0.82 e Å3
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refinement of F2 against all reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on all data will be even larger.
xyzUiso*/Ueq
Br10.99854 (9)−0.03225 (4)0.83292 (4)0.0624 (2)
N10.3023 (6)0.4132 (3)0.9218 (3)0.0429 (6)
H10.17810.38230.98270.052*
C10.3081 (8)0.5487 (4)0.8627 (3)0.0438 (7)
O10.1416 (6)0.6472 (3)0.8854 (2)0.0545 (6)
N20.5408 (7)0.5549 (3)0.7722 (3)0.0463 (7)
C20.6765 (8)0.4238 (4)0.7739 (3)0.0448 (8)
N30.9047 (7)0.3902 (3)0.7003 (3)0.0536 (7)
C30.9924 (8)0.2536 (4)0.7221 (4)0.0537 (9)
H31.15270.22270.67330.064*
C40.8551 (8)0.1578 (4)0.8137 (3)0.0474 (8)
C50.6169 (8)0.1954 (3)0.8914 (3)0.0446 (7)
H50.52600.13160.95410.054*
C60.5261 (7)0.3327 (3)0.8692 (3)0.0400 (7)
C70.6297 (9)0.6836 (4)0.6904 (4)0.0577 (10)
H7A0.84500.67930.66980.069*
H7B0.57860.76220.73020.069*
C80.4822 (12)0.7071 (5)0.5791 (4)0.0727 (13)
H80.48560.63300.53930.087*
C90.3510 (13)0.8229 (7)0.5349 (5)0.0923 (17)
H9A0.34350.89910.57250.111*
H9B0.26370.83040.46530.111*
U11U22U33U12U13U23
Br10.0653 (3)0.0414 (3)0.0810 (4)0.01520 (18)−0.0026 (2)−0.0228 (2)
N10.0438 (15)0.0317 (14)0.0475 (15)0.0066 (11)0.0071 (11)−0.0044 (11)
C10.0459 (18)0.0326 (17)0.0504 (19)0.0017 (14)−0.0002 (14)−0.0063 (14)
O10.0569 (15)0.0348 (13)0.0660 (16)0.0104 (11)0.0037 (12)−0.0068 (11)
N20.0450 (15)0.0336 (14)0.0549 (17)0.0030 (12)0.0027 (13)−0.0028 (12)
C20.0404 (17)0.0413 (18)0.0519 (19)0.0003 (14)−0.0030 (14)−0.0091 (15)
N30.0468 (16)0.0506 (18)0.0585 (18)0.0027 (13)0.0070 (13)−0.0084 (14)
C30.0443 (19)0.056 (2)0.060 (2)0.0073 (16)0.0025 (16)−0.0189 (18)
C40.0459 (18)0.0427 (18)0.056 (2)0.0057 (14)−0.0047 (15)−0.0181 (15)
C50.0457 (18)0.0352 (17)0.0512 (19)0.0023 (14)−0.0001 (14)−0.0089 (14)
C60.0383 (16)0.0344 (16)0.0464 (18)0.0013 (13)−0.0010 (13)−0.0095 (13)
C70.051 (2)0.042 (2)0.072 (2)−0.0067 (16)0.0028 (18)0.0043 (17)
C80.101 (4)0.058 (3)0.051 (2)−0.010 (2)0.009 (2)0.000 (2)
C90.094 (4)0.102 (5)0.068 (3)−0.005 (3)−0.007 (3)0.014 (3)
Br1—C41.905 (4)C3—H30.9300
N1—C11.367 (4)C4—C51.387 (5)
N1—C61.388 (4)C5—C61.361 (5)
N1—H10.8600C5—H50.9300
C1—O11.228 (4)C7—C81.498 (7)
C1—N21.379 (5)C7—H7A0.9700
N2—C21.380 (5)C7—H7B0.9700
N2—C71.465 (5)C8—C91.286 (8)
C2—N31.315 (5)C8—H80.9300
C2—C61.406 (5)C9—H9A0.9300
N3—C31.351 (5)C9—H9B0.9300
C3—C41.381 (6)
C1—N1—C6110.1 (3)C6—C5—C4115.0 (3)
C1—N1—H1124.9C6—C5—H5122.5
C6—N1—H1124.9C4—C5—H5122.5
O1—C1—N1127.3 (3)C5—C6—N1134.3 (3)
O1—C1—N2126.0 (3)C5—C6—C2119.5 (3)
N1—C1—N2106.8 (3)N1—C6—C2106.3 (3)
C1—N2—C2109.5 (3)N2—C7—C8112.6 (3)
C1—N2—C7124.0 (3)N2—C7—H7A109.1
C2—N2—C7126.4 (3)C8—C7—H7A109.1
N3—C2—N2126.4 (3)N2—C7—H7B109.1
N3—C2—C6126.3 (3)C8—C7—H7B109.1
N2—C2—C6107.3 (3)H7A—C7—H7B107.8
C2—N3—C3114.0 (3)C9—C8—C7124.4 (5)
N3—C3—C4123.0 (3)C9—C8—H8117.8
N3—C3—H3118.5C7—C8—H8117.8
C4—C3—H3118.5C8—C9—H9A120.0
C3—C4—C5122.2 (3)C8—C9—H9B120.0
C3—C4—Br1118.6 (3)H9A—C9—H9B120.0
C5—C4—Br1119.2 (3)
D—H···AD—HH···AD···AD—H···A
N1—H1···O1i0.861.952.798 (4)168
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯AD—HH⋯ADAD—H⋯A
N1—H1⋯O1i0.861.952.798 (4)168

Symmetry code: (i) .

  5 in total

1.  Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists.

Authors:  Santosh S Kulkarni; Amy Hauck Newman
Journal:  Bioorg Med Chem Lett       Date:  2007-03-24       Impact factor: 2.823

2.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

3.  Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.

Authors:  Andrea Cappelli; Gal la Pericot Mohr; Germano Giuliani; Simone Galeazzi; Maurizio Anzini; Laura Mennuni; Flora Ferrari; Francesco Makovec; Eva M Kleinrath; Thierry Langer; Massimo Valoti; Gianluca Giorgi; Salvatore Vomero
Journal:  J Med Chem       Date:  2006-11-02       Impact factor: 7.446

4.  Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.

Authors:  Vassilios Bavetsias; Jonathan M Large; Chongbo Sun; Nathalie Bouloc; Magda Kosmopoulou; Mizio Matteucci; Nicola E Wilsher; Vanessa Martins; Jóhannes Reynisson; Butrus Atrash; Amir Faisal; Frederique Urban; Melanie Valenti; Alexis de Haven Brandon; Gary Box; Florence I Raynaud; Paul Workman; Suzanne A Eccles; Richard Bayliss; Julian Blagg; Spiros Linardopoulos; Edward McDonald
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

5.  Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases.

Authors:  Vassilios Bavetsias; Chongbo Sun; Nathalie Bouloc; Jóhannes Reynisson; Paul Workman; Spiros Linardopoulos; Edward McDonald
Journal:  Bioorg Med Chem Lett       Date:  2007-10-22       Impact factor: 2.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.